Risk factors for pregnancy outcomes in Type 1 and Type 2 diabetes.


Journal

Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 14 08 2019
revised: 04 02 2020
accepted: 21 03 2020
pubmed: 3 4 2020
medline: 1 6 2021
entrez: 3 4 2020
Statut: ppublish

Résumé

Understanding the risk factors and pregnancy outcomes in women affected by Type 1 and Type 2 diabetes is important for pre-pregnancy counselling. To explore differences in pregnancy outcomes between women with Type 1 and Type 2 diabetes, and healthy controls, and to examine the relationships between potential adverse risk factors and pregnancy outcomes in this cohort of women. This is a 10-year retrospective study of women with Type 1 diabetes (n = 92), Type 2 diabetes (n = 106) and healthy women without diabetes (controls) (n = 119) from a tertiary obstetric centre. Clinical and biochemical characteristics of women with Type 1 and Type 2 diabetes were determined and related to major obstetric outcomes using univariate analysis. Women with pre-existing diabetes had higher adverse pregnancy outcomes (preeclampsia, emergency caesarean section, preterm birth <32 and 37 weeks, large for gestational age, neonatal jaundice, Apgar score < 7 at 5 min, neonatal intensive care admission and neonatal hypoglycaemia) compared to controls. A higher birth weight gestational centile (97.4% vs 72.4%, P = 0.001) and large for gestational age rate (63.4% vs 35.8%, P = 0.001) were observed in Type 1 diabetes compared to Type 2 diabetes. There were no differences in other outcomes between women with Type 1 and 2 diabetes. In this exploratory study, risk factors for maternal adverse outcomes differ between Type 1 and Type 2 diabetes. Maternal and foetal adverse outcomes were higher in pregnancies affected by diabetes compared to healthy women but occurred with similar frequency in women with Type 1 and Type 2 diabetes.

Sections du résumé

BACKGROUND BACKGROUND
Understanding the risk factors and pregnancy outcomes in women affected by Type 1 and Type 2 diabetes is important for pre-pregnancy counselling.
AIM OBJECTIVE
To explore differences in pregnancy outcomes between women with Type 1 and Type 2 diabetes, and healthy controls, and to examine the relationships between potential adverse risk factors and pregnancy outcomes in this cohort of women.
METHODS METHODS
This is a 10-year retrospective study of women with Type 1 diabetes (n = 92), Type 2 diabetes (n = 106) and healthy women without diabetes (controls) (n = 119) from a tertiary obstetric centre. Clinical and biochemical characteristics of women with Type 1 and Type 2 diabetes were determined and related to major obstetric outcomes using univariate analysis.
RESULTS RESULTS
Women with pre-existing diabetes had higher adverse pregnancy outcomes (preeclampsia, emergency caesarean section, preterm birth <32 and 37 weeks, large for gestational age, neonatal jaundice, Apgar score < 7 at 5 min, neonatal intensive care admission and neonatal hypoglycaemia) compared to controls. A higher birth weight gestational centile (97.4% vs 72.4%, P = 0.001) and large for gestational age rate (63.4% vs 35.8%, P = 0.001) were observed in Type 1 diabetes compared to Type 2 diabetes. There were no differences in other outcomes between women with Type 1 and 2 diabetes.
CONCLUSION CONCLUSIONS
In this exploratory study, risk factors for maternal adverse outcomes differ between Type 1 and Type 2 diabetes. Maternal and foetal adverse outcomes were higher in pregnancies affected by diabetes compared to healthy women but occurred with similar frequency in women with Type 1 and Type 2 diabetes.

Identifiants

pubmed: 32237194
doi: 10.1111/imj.14840
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

78-86

Subventions

Organisme : Royal Australasian College of Physicians
Organisme : RACP-JDRF Research Establishment Fellowship

Informations de copyright

© 2020 Royal Australasian College of Physicians.

Références

Yang J, Cummings EA, O'Connell C, Jangaard K. Fetal and neonatal outcomes of diabetic pregnancies. Obstet Gynecol 2006; 108: 644-50.
Jensen DM, Damm P, Moelsted-Pedersen L, Ovesen P, Westergaard JG, Moeller M et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care 2004; 27: 2819-23.
Australian Institute of Health and Welfare. Diabetes in Pregnancy: Its Impact on Australian Women and Their Babies. The Institute: Canberra; 2010.
Cheung NW, McElduff A, Ross GP. Type 2 diabetes in pregnancy: a wolf in sheep's clothing. Aust N Z J Obstet Gynaecol 2005; 45: 479-83.
McElduff A, Ross GP, Lagstrom JA, Champion B, Flack JR, Lau SM et al. Pregestational diabetes and pregnancy: an Australian experience. Diabetes Care 2005; 28: 1260-1.
Jovanovic L, Liang Y, Weng W, Hamilton M, Chen L, Wintfeld N. Trends in the incidence of diabetes, its clinical sequelae, and associated costs in pregnancy. Diabetes Metab Res Rev 2015; 31: 707-16.
Holmes VA, Young IS, Patterson CC, Pearson DW, Walker JD, Maresh MJ et al. Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial. Diabetes Care 2011; 34: 1683-8.
Ekinci EI, Lu ZX, Sikaris K, Bittar I, Cheong KY, Lam Q et al. Longitudinal assessment of thyroid function in pregnancy. Ann Clin Biochem 2013; 50: 595-602.
Ekinci EI, Chiu WL, Lu ZX, Sikaris K, Churilov L, Bittar I et al. A longitudinal study of thyroid autoantibodies in pregnancy: the importance of test timing. Clin Endocrinol (Oxf) 2015; 82: 604-10.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Statements and Guidelines. Melbourne: RANZCOG [cited 2017 May 12]. Available from URL: https://www.ranzcog.edu.au/Statements-Guidelines/
Mongelli M, Figueras F, Francis A, Gardosi J. A customized birthweight centile calculator developed for an Australian population. Aust N Z J Obstet Gynaecol 2007; 47: 128-31.
Boulot P, Chabbert-Buffet N, d'Ercole C, Floriot M, Fontaine P, Fournier A et al. French multicentric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care 2003; 26: 2990-3.
Clausen TD, Mathiesen E, Ekbom P, Hellmuth E, Mandrup-Poulsen T, Damm P. Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care 2005; 28: 323-8.
Dunne F, Brydon P, Smith K, Gee H. Pregnancy in women with type 2 diabetes: 12 years outcome data 1990-2002. Diabet Med 2003; 20: 734-8.
Cundy T, Gamble G, Townend K, Henley PG, MacPherson P, Roberts AB. Perinatal mortality in type 2 diabetes mellitus. Diabet Med 2000; 17: 33-9.
Hillman N, Herranz L, Vaquero PM, Villarroel A, Fernandez A, Pallardo LF. Is pregnancy outcome worse in type 2 than in type 1 diabetic women? Diabetes Care 2006; 29: 2557-8.
Pregnancy outcomes in the diabetes control and complications trial. Am J Obstet Gynecol 1996; 174: 1343-53.
Nahavandi S, Seah JM, Shub A, Houlihan C, Ekinci EI. Biomarkers for macrosomia prediction in pregnancies affected by diabetes. Front Endocrinol (Lausanne) 2018; 9: 407.
Maresh MJ, Holmes VA, Patterson CC, Young IS, Pearson DW, Walker JD et al. Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes. Diabetes Care 2015; 38: 34-42.
Kerssen A, de Valk HW, Visser GH. Increased second trimester maternal glucose levels are related to extremely large-for-gestational-age infants in women with type 1 diabetes. Diabetes Care 2007; 30: 1069-74.
Inkster ME, Fahey TP, Donnan PT, Leese GP, Mires GJ, Murphy DJ. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: systematic review of observational studies. BMC Pregnancy Childbirth 2006; 6: 30.
Nielsen LR, Ekbom P, Damm P, Glumer C, Frandsen MM, Jensen DM et al. HbA1c levels are significantly lower in early and late pregnancy. Diabetes Care 2004; 27: 1200-1.
Murphy HR, Rayman G, Lewis K, Kelly S, Johal B, Duffield K et al. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ 2008; 337: a1680.
Feig DS, Donovan LE, Corcoy R, Murphy KE, Amiel SA, Hunt KF et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet 2017; 390: 2347-59.
Radulescu L, Munteanu O, Popa F, Cirstoiu M. The implications and consequences of maternal obesity on fetal intrauterine growth restriction. J Med Life 2013; 6: 292-8.
Xu Z, Wen Z, Zhou Y, Li D, Luo Z. Inadequate weight gain in obese women and the risk of small for gestational age (SGA): a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2017; 30: 357-67.
Institute of Medicine (US) Committee on Nutritional Status During Pregnancy and Lactation. Nutrition During Pregnancy: Part I Weight Gain: Part II Nutrient Supplements. Washington: National Academies Press; 1990.
Sovio U, Murphy HR, Smith GC. Accelerated fetal growth prior to diagnosis of gestational diabetes mellitus: a prospective cohort study of nulliparous women. Diabetes Care 2016; 39: 982-7.
Abell SK, Boyle JA, de Courten B, Soldatos G, Wallace EM, Zoungas S et al. Impact of type 2 diabetes, obesity and glycaemic control on pregnancy outcomes. Aust N Z J Obstet Gynaecol 2017; 57: 308-14.
Abell SK, Boyle JA, de Courten B, Knight M, Ranasinha S, Regan J et al. Contemporary type 1 diabetes pregnancy outcomes: impact of obesity and glycaemic control. Med J Aust 2016; 205: 162-7.
Catov JM, Nohr EA, Olsen J, Ness RB. Chronic hypertension related to risk for preterm and term small for gestational age births. Obstet Gynecol 2008; 112: 290-6.
Yanit KE, Snowden JM, Cheng YW, Caughey AB. The impact of chronic hypertension and pregestational diabetes on pregnancy outcomes. Am J Obstet Gynecol 2012; 207: 333.e1-6.
Nielsen LR, Damm P, Mathiesen ER. Improved pregnancy outcome in type 1 diabetic women with microalbuminuria or diabetic nephropathy: effect of intensified antihypertensive therapy? Diabetes Care 2009; 32: 38-44.
Carr DB, Koontz GL, Gardella C, Holing EV, Brateng DA, Brown ZA et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens 2006; 19: 513-9.
Diabetes Australia. Data Snapshot - Type 1 Diabetes in National Diabetes Service Scheme Statistics. Australia: National Diabetes Service Scheme; 2018.
Diabetes Australia. Data Snapshot - Type 2 Diabetes in National Diabetes Service Scheme Statistics. Australia: National Diabetes Service Scheme; 2018.

Auteurs

Jas-Mine Seah (JM)

Department of Perinatal Medicine, Mercy Health, Melbourne, Victoria, Australia.
Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia.
Department of Medicine Austin Health, The University of Melbourne, Melbourne, Victoria, Australia.

Ning M Kam (NM)

Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia.
Department of Medicine Austin Health, The University of Melbourne, Melbourne, Victoria, Australia.

Lydia Wong (L)

Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia.

Cara Tanner (C)

Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia.
Department of Medicine Austin Health, The University of Melbourne, Melbourne, Victoria, Australia.

Alexis Shub (A)

Department of Perinatal Medicine, Mercy Health, Melbourne, Victoria, Australia.
Department of Medicine Austin Health, The University of Melbourne, Melbourne, Victoria, Australia.

Christine Houlihan (C)

Department of Perinatal Medicine, Mercy Health, Melbourne, Victoria, Australia.
Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia.

Elif I Ekinci (EI)

Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia.
Department of Medicine Austin Health, The University of Melbourne, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH